Iclusig

Ponatinib, the active ingredient in Iclusig, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia that are resistant or intolerant to prior therapy, targeting the BCR‑ABL kinase—including the T315I mutation—and other kinases involved in tumor cell proliferation.

GNH USA supplies Iclusig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑assured delivery and regulatory compliance across multiple regions.

Iclusig (ponatinib) is used to treat malignancies driven by the BCR‑ABL tyrosine kinase pathway. - Chronic myeloid leukemia (CML): provides disease control in patients who are resistant or intolerant to prior tyrosine kinase inhibitor therapy. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): offers a therapeutic option for patients with resistance or intolerance to earlier treatments. - BCR‑ABL positive leukemias with T315I mutation: targets the resistant mutation to restore treatment efficacy.

Ponatinib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Diarrhea - Rash - Hypertension - Fatigue - Headache

Serious or Rare Side Effects: - Arterial occlusive events (e.g., myocardial infarction, stroke) - Severe hypertension - Hepatotoxicity (elevated liver enzymes, hepatitis) - Pancreatitis - Cardiac failure - Venous thromboembolism

When prescribing ponatinib, clinicians should observe several precautionary measures to minimize risk. - Blood pressure monitoring: check and control hypertension regularly during treatment. - Liver function tests: assess hepatic enzymes before initiation and periodically thereafter. - Pancreatic enzymes: monitor amylase and lipase levels to detect pancreatitis early. - Cardiovascular risk assessment: avoid use in patients with recent arterial events or uncontrolled cardiovascular disease. - Drug interactions: review concomitant medications for CYP3A4 modulators and anticoagulants. - Store at room temperature: keep tablets in the original packaging, protect from moisture and excessive heat.

Ponatinib interacts with several medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ponatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug levels. - Anticoagulants (e.g., warfarin): heightened risk of bleeding when combined with ponatinib.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: ponatinib can exacerbate hypertension, requiring dose adjustments. - Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin concentrations, monitor for myopathy. - Other tyrosine kinase inhibitors: additive toxicity potential, monitor patient closely. - QT‑prolonging drugs: may increase risk of cardiac arrhythmias, observe ECG.